The drug Sofosbuvir – 1-th product for a protracted cure of hepatitis C, significantly eye-catching with its own predecessors. Directly with the emergence of Sofosbuvir enterovirus Sofosbuvir disease C ceased to be regarded as well as a deadly disease, in the treatment of which it is possible to achieve only long-term remission, but not an absolute cure. In 2013, the pharmaceutical company Gilead bases the production of a unique substance «Sovaldi», the main functioning element of which is considered Sofosbuvir. This treatment method was approved and allowed to be used by the FDA (North American Council for the control of the properties of pharmaceutical substances). Multiple medical tests of Sofosbuvir have shown:

excellent efficacy (one HUNDRED PERCENT onkoginekologicheskih result in almost absolutely all patients);
short-term use (overall 12 months absolute direction contrary to 24 and 48 in the case of interferon therapy);
high security and excellent transportability.
Dignity Sophospoweruser of cure with Sofosbuvir existed included in all publications (scientific society) cure of prolonged hepatitis C. To date, the Hindu period and demotic pharmaceutical companies make generics – medications such because a functioning element, in this case with Sofosbuvir; however, according to substantially the lowest value. The reduction in the price of anti-virus therapy creates an easily accessible possibility of absolute treatment for the largest number of people infected with HCV.